Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 9/20 | 0.45 |
| ▸ | PPARA | Q07869 | 9/20 | 0.45 |
| ▸ | CNR1 | P21554 | 4/20 | 0.42 |
| ▸ | CNR2 | P34972 | 4/20 | 0.39 |
| ▸ | LAP3 | P28838 | 4/20 | 0.39 |
| ▸ | ANPEP | P15144 | 1/20 | 0.39 |
| ▸ | ACP3 | P15309 | 1/20 | 0.38 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1810262 | 0.92 | ACP3 (0.45) | LAP3ANPEPACP3 | |
| SCHEMBL1809667 | 0.87 | PPARG (0.48) | PPARGPPARACNR1CNR2ACP3 | |
| SCHEMBL1808145 | 0.85 | NPC1 (0.46) | ANPEP | |
| SCHEMBL1811461 | 0.84 | CYP1A2 (0.39) | PPARGPPARA | |
| SCHEMBL1809439 | 0.79 | ALDH1A1 (0.39) | ANPEPACP3 | |
| SCHEMBL1814697 | 0.77 | CYP1A2 (0.39) | PPARA | |
| SCHEMBL1811752 | 0.71 | CYP1A2 (0.41) | ANPEPACP3 | |
| SCHEMBL13113806 | 0.70 | SLC6A4 (0.50) | PPARGPPARACNR1CNR2 | |
| SCHEMBL1809384 | 0.69 | GRM8 (0.43) | — | |
| Hydrochloric Acid SCHEMBL3520217 | 0.69 | SLC6A2 (0.48) | PPARGPPARACNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3904365-A1 | CHEMICAL COMPOUNDS | NuCana plc (GB) | 2021-11-03 | — | — | EP | disclosed |
| US-RE47589-E1 | Phosphoramidate compounds and methods of use | NuCana plc (GB) | 2019-09-03 | — | — | US | disclosed |
| EP-3486251-A1 | CHEMICAL COMPOUNDS | NuCana plc (GB) | 2019-05-22 | — | — | EP | disclosed |
| EP-3040340-B1 | CHEMICAL COMPOUNDS | NuCana plc (GB) | 2018-11-14 | — | — | EP | disclosed |
| EP-2955190-B1 | Chemical compounds | NuCana plc (GB) | 2018-03-28 | — | — | EP | disclosed |
| EP-1646639-B1 | NUCLEOTIDE PHOSPHORAMIDATES AS ANTICANCER AGENTS | NUCANA BIOMED LTD (GB) | 2016-08-17 | — | — | EP | disclosed |
| EP-3040340-A1 | CHEMICAL COMPOUNDS | NuCana BioMed Limited (GB) | 2016-07-06 | — | — | EP | disclosed |
| EP-2955190-A2 | Chemical compounds | NuCana BioMed Limited (GB) | 2015-12-16 | — | — | EP | disclosed |
| US-7951787-B2 | Phosphoramidate compounds and methods of use | CARDIFF PROTIDES LIMITED (GB) | 2011-05-31 | — | — | US | disclosed |
| US-20060142238-A1 | Chemical compounds | NuCana plc (GB) | 2006-06-29 | — | — | US | disclosed |
| EP-1646639-A2 | NUCLEOTIDE PHOSPHORAMIDATES AS ANTICANCER AGENTS | University College Cardiff Consultants, Ltd. (GB) | 2006-04-19 | — | — | EP | disclosed |
| WO-2005012327-A2 | NUCLEOTIDE PHOSPHORAMIDATES AS ANTICANCER AGENTS | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142238-A1 | Chemical compounds | NUDT1, DCK, PNP | PPARG 898/4885PPARA 570/4885CNR1 1249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.